Statins may soon be routinely prescribed to people who have suffered a stroke through international medical insurance policies, new research has indicated.
The study, which was published in the American Academy of Neurology's medical journal Neurology, found these cholesterol-lowering medications may make individuals who have had a stroke more likely to return home, while cutting the chance of them dying in hospital.
Researchers determined statin use by examining pharmacy and medical records, detailing who was using these drugs before they were hospitalised and during their stroke treatment.
A total of 12,689 people were examined in the research, with all of these individuals admitted to northern California's Kaiser Permanente hospital suffering from an ischemic stroke.
This illness occurs when one of the blood vessels supplying the brain becomes blocked, rather than a hemorrhagic stroke, which is when there is bleeding into or around this organ.
Neural cells due when these events occur, resulting in symptoms such as weakness, numbness, difficulty talking or understanding speech, severe headaches and issues with vision.
Members of the public who had utilised statins before they were hospitalised or during their stay in the medical centre returned home in 57 per cent of all stroke cases, compared with 47 per cent of those who had not taken the drugs.
Furthermore, while 11 per cent of the people who did not use statins died in hospital, this figure was just six per cent among those that had taken the medicines.
The other potential outcome of the hospital visit was being discharged to nursing homes, rehabilitation centres or other institutions.
Alexander Flint, a member of the American Academy of Neurology, was one of the authors of the study.
He said: "There are a multitude of benefits to returning directly home after experiencing a stroke for the patient and the family, both functionally and financially."
"Statins are known to reduce the risk of further strokes, but the timing of when a statin should be started has been unclear," the expert added.